- Report
- July 2025
- 386 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Clinical Trials
- April 2025
- 3092 Pages
Global
From €3031EUR$3,450USD£2,615GBP
- Report
- October 2024
- 220 Pages
Global
From €4217EUR$4,799USD£3,637GBP
- Report
- November 2024
- 173 Pages
Global
From €4086EUR$4,650USD£3,524GBP
- Report
- October 2024
- 298 Pages
Global
From €4349EUR$4,950USD£3,752GBP
- Report
- October 2024
- 190 Pages
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- November 2024
Global
From €4745EUR$5,400USD£4,093GBP
- Report
- December 2024
- 100 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- May 2025
- 184 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 193 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 182 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 183 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 182 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 192 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 185 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 191 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 183 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 196 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 189 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 183 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more